Table 3 Risk factors for developing pneumothorax in patients with sarcoma and metastatic disease to the chest
Covariate | Univariate model | Multivariate model | ||||||
|---|---|---|---|---|---|---|---|---|
OR | 95% CI | P-value | OR | 95% CI | P-value | |||
Age | 0.981 | 0.963 | 0.999 | .041 | ||||
Male | 2.73 | 1.303 | 5.719 | .008 | ||||
Race | ||||||||
White | 1.000 | |||||||
African American | 4.047 | 1.589 | 10.307 | .003 | ||||
Hispanic/Other | 1.827 | 0.780 | 1.278 | .164 | ||||
Cavitary lung nodule/mass | 6.162 | 2.954 | 12.855 | <.001 | 7.024 | 3.023 | 16.315 | <.001 |
Pleural base lung nodule/mass | 9.596 | 3.817 | 24.123 | <.001 | 10.390 | 3.824 | 28.230 | <.001 |
Emphysema present | 8.358 | 0.739 | 94.54 | .086 | ||||
Prior radiation to the chest present | 2.025 | 0.179 | 22.893 | .569 | ||||
Patient was receiving pazopanib | 2.408 | 0.943 | 6.147 | .06 | ||||